| Dr Yat Hong Lau, MD | |
|
230 Nebraska St, Sioux City, IA 51101-1733 | |
| (712) 252-9390 | |
| (712) 252-9404 |
| Full Name | Dr Yat Hong Lau |
|---|---|
| Gender | Male |
| Speciality | Radiology - Radiation Oncology |
| Location | 230 Nebraska St, Sioux City, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235234279 | NPI | - | NPPES |
| 0483628 | Medicaid | IA | |
| 14795 | Other | IA | WELLMARK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 36483 (Iowa) | Primary |
| 2085R0001X | Radiology - Radiation Oncology | 5820 (South Dakota) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yat Hong Lau, MD Po Box 5017, Sioux City, IA 51102-5017 Ph: (712) 252-9390 | Dr Yat Hong Lau, MD 230 Nebraska St, Sioux City, IA 51101-1733 Ph: (712) 252-9390 |
News Archive
"Jon Kingsdale, head of the quasi-state agency that oversees Massachusetts' landmark health law, is stepping down June 4, Governor Deval Patrick said yesterday."
Birner Dental Management Services, Inc., operators of PERFECT TEETH dental practices and Vantage Dental Implant Center, announced its regular quarterly dividend. The Company's board of directors has declared a quarterly cash dividend of 22 cents per share of common stock. The dividend is payable October 14, 2011, to shareholders of record September 30, 2011.
Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.
In the first large-scale effort of its kind, researchers have determined the full genetic sequence of more than 200 distinct strains of human influenza virus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 9 days ago
Donald Schenk, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 801 5th St, Sioux City, IA 51101 Phone: 308-647-4900 Fax: 308-647-5378 | |
James C Beeler, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 5 Harvest Rd, Sioux City, IA 51104 Phone: 712-239-0521 | |
Sheila Marie Foster, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Stone Park Blvd, Sioux City, IA 51104 Phone: 712-279-3285 | |
Jonathan C Beeler, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 801 5th St, Sioux City, IA 51101 Phone: 308-647-4900 Fax: 308-647-5378 | |
James Joseph Goebel, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 2720 Stone Park Blvd, Sioux City, IA 51104 Phone: 712-279-3285 | |
Todd Russell Stephens, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Stone Park Blvd, Sioux City, IA 51104 Phone: 712-279-3285 |